Clinical trials: Digestive Disease
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
Does the novel drug decrease liver fat in subjects with NASH or NAFLD as compared to placebo
- Trial name
- NCT02605616
- Testing
- AZ compound
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
Based on previous clinical findings, the investigator hypothesize that ivacaftor will have synergistic effects with drugs that facilitate truncated but partially active W1282X CFTR protein processing (tezacaftor) in patients with…
- Trial name
- NCT03624101
- Testing
- Symdeko, Ivacaftor and Symdeko
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Colorectal Cancer
A Study of Mitomycin C, Irinotecan, and Cetuximab
Colorectal cancer (CRC) is one of the more common cancers in the United States with over 145,000 new cases expected in 2005. Surgery is the main treatment for CRC.
- Trial name
- NCT00271011
- Testing
- Mitomycin C, Cetuximab, Irinotecan.
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Michigan Rogel Cancer Center
Pain, Cancer
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy.
- Conditions
- Pain, Cancer, Colonic Diseases
- Trial name
- NCT01926444
- Testing
- GIC-1001
- Where
- 15 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- gicare Pharma Inc.
Immune Evasion, Tumor, Neoplastic Cells, Circulating
Immune Mechanisms After Radiofrequency Ablation of Pulmonary Metastases From Colorectal Cancer Origin
Local percutaneous thermal ablation is frequently proposed in the management of metastatic diseases. Radiofrequency ablation (RFA) has demonstrated good results when the metastatic disease is limited and slowly evolving.
- Conditions
- Immune Evasion, Tumor, Neoplastic Cells, Circulating, Circulating Tumor Cell, Pulmonary Metastasis
- Trial name
- ARFIM (NCT03960021)
- Testing
- RFA interventions
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Bergonié
Metastatic Pancreatic Adenocarcinoma
FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer
This study will enroll patients who have metastatic pancreatic cancer with stable disease on FOLFIRINOX chemotherapy. The main purpose of this study is to compare survival between patients that receive ipilimumab and a pancreatic…
- Trial name
- NCT01896869
- Testing
- Ipilimumab, Vaccine, FOLFIRINOX
- Where
- 3 sites in United States
- Volunteers
- 83 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ulcerative Colitis
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
The purpose of this study is to evaluate efficacy, safety and pharmacokinetics of the vedolizumab (MLN0002) induction and maintenance therapy in Japanese participants with moderate or severe ulcerative colitis (UC).
- Trial name
- NCT02039505
- Testing
- Vedolizumab
- Where
- 59 sites in Japan
- Volunteers
- 292 people
- Sponsor
- Takeda
Esophageal Cancer
Phase II Study of Irinotecan and Panitumumab
This study proposes a single-arm, phase II study of irinotecan with panitumumab as second-line therapy for patients with advanced esophageal adenocarcinoma.
- Trial name
- NCT00836277
- Testing
- Panitumumab, Irinotecan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weijing Sun, MD, FACP
Opioid-induced Constipation
Compassionate Use Study of Methylnaltrexone
This is an open label compassionate use study of subcutaneously administered methylnaltrexone (MNTX) in participants with advance medical illness and opioid-induced constipation.
- Trial name
- NCT01368562
- Testing
- Methylnaltrexone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Bausch Health Americas, Inc.
Dyspepsia, Irritable Bowel Syndrome
A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-G
A randomized, sham-controlled, single-centre pilot investigation designed to compare two parallel groups, gammaCore®-G (active treatment) and a sham, (inactive) treatment in subjects with FGIDs.
- Trial name
- NCT02388269
- Testing
- gammaCore®-G
- Where
- United Kingdom
- Volunteers
- 91 people
- Sponsor
- ElectroCore INC
Portal Hypertension
Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension
The primary purpose of this study is to determine the efficacy and safety of cobiprostone (at two dose levels) as compared to placebo for lowering portal hypertension.
- Trial name
- NCT00737594
- Testing
- Cobiprostone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sucampo Pharma Americas, LLC
Colon Cancer
Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
A major limitation to the widespread acceptance of colonoscopy as a procedure to screen for colorectal cancer is the laxative preparation. Phosphate-based preps (e.g.
- Trial name
- NCT01170754
- Testing
- PEG-3350 and Gatorade, Golytely 4 liters
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Temple University
Bladder Cancer, Pancreas Cancer
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
This multicenter, non-randomized, Phase II study will assess the efficacy, safety, and pharmacokinetics of trastuzumab emtansine in participants with HER2 overexpressing locally advanced (unresectable and not treatable with…
- Conditions
- Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
- Trial name
- KAMELEON (NCT02999672)
- Testing
- Trastuzumab Emtansine
- Where
- 16 sites in Italy, Netherlands and 2 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Stomach Neoplasms
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
The purpose of this study is to determine the safe and tolerable dose of sunitinib when given together with cisplatin and 5-fluorouracil in patients with advanced gastric cancer who have not received prior chemotherapy for their…
- Trial name
- NCT00555672
- Testing
- 5-fluorouracil, cisplatin, sunitinib malate
- Where
- 3 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Pfizer
Pancreatic Cancer
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.
- Trial name
- NCT01342354
- Testing
- Stereotactic Radiation 10 Gy, Stereotactic Radiation 12.5 Gy, Stereotactic Radiation 15 Gy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago
Biliary Tract Neoplasms
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
The purpose of this trial is to evaluate the effect of investigational drug nivolumab in combination with either gemcitabine/cisplatin chemotherapy, or in combination with another investigational agent ipilimumab in patients with…
- Trial name
- NCT03101566
- Testing
- Gemcitabine, Cisplatin, Ipilimumab
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Opioid-Induced Constipation
Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness
This study will evaluate the safety and efficacy of methylnaltrexone administered as subcutaneous injections in subjects who have opioid-induced constipation and an advanced illness.
- Trial name
- NCT00672477
- Testing
- Methylnaltrexone
- Where
- 60 sites in United States, Australia and 10 more
- Volunteers
- 237 people
- Sponsor
- Bausch Health Americas, Inc.
Colorectal Cancer
Decision Aid to Technologically Enhance Shared Decision Making
Physicians face a challenge in promoting colorectal cancer screening (CRCS) in the face of multiple competing demands. A decision aid (DA) that clarifies patient preferences and improves decision quality could aid shared decision…
- Trial name
- DATES (NCT01514786)
- Testing
- Colorectal Web
- Where
- 14 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Carcinoma, Hepatocellular
A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.
- Trial name
- NCT02069041
- Testing
- Ramucirumab, FOLFOX4
- Where
- 3 sites in Taiwan
- Volunteers
- 8 people
- Sponsor
- Eli Lilly and Company
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
This open-label, multi-center study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with standard chemotherapy as first-line treatment in patients with HER2 positive metastatic adenocarcinoma of…
- Trial name
- NCT01260194
- Testing
- trastuzumab [Herceptin]
- Where
- 6 sites in India
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.